Results - Analysis
Sales up 20.46%, while NP down 1.42%
On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Jupiter Life Line Hospitals has increased 20.46% to Rs 347.63 crore. Operating profit margin has declined from 22.64% to 22.48%, leading to 19.61% rise in operating profit to Rs 78.13 crore. Purchase of finished goods cost rose from 18.34% to 19.75%. Employee cost decreased from 17.56% to 17.08%. Other expenses fell from 41.72% to 40.72%. Selling and administration expenses fell from 24.05% to 23.78%.
Other income rose 86.25% to Rs 12.87 crore. PBIDT rose 25.99% to Rs 91 crore. Provision for interest rose 664.81% to Rs 8.26 crore.
PBDT rose 16.29% to Rs 82.74 crore. Provision for depreciation rose 92.73% to Rs 21.2 crore.
Profit before tax grew 2.31% to Rs 61.54 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 17.66 crore, compared to Rs 15.54 crore. Effective tax rate was 28.70% compared to 25.84%.
Minority interest decreased 71.43% to Rs 0.04 crore. Net profit attributable to owners of the company decreased 1.42% to Rs 43.84 crore.Promoters' stake was 40.91% as of 30 June 2025 ,compared to 40.91% as of 30 June 2024 .
Net sales (including other operating income) of Jupiter Life Line Hospitals has increased 17.52% to Rs 1261.55 crore. Operating profit margin has jumped from 22.55% to 23.51%, leading to 22.50% rise in operating profit to Rs 296.55 crore. Purchase of finished goods cost rose from 17.83% to 18.42%. Employee cost decreased from 17.66% to 16.97%. Other expenses fell from 42.01% to 41.16%. Selling and administration expenses fell from 25.22% to 24.21%.
Other income rose 30.07% to Rs 28.68 crore. PBIDT rose 23.13% to Rs 325.23 crore. Provision for interest fell 59.95% to Rs 10.55 crore. Loan funds remained nil. Inventories rose to Rs 24.10 crore as of 31 March 2025 from Rs 21.34 crore as of 31 March 2024. Sundry debtors were lower at Rs 41.89 crore as of 31 March 2025 compared to Rs 57.21 crore as of 31 March 2024. Cash and bank balance rose to Rs 488.67 crore as of 31 March 2025 from Rs 301.25 crore as of 31 March 2024. Investments rose to Rs 114.40 crore as of 31 March 2025 from Rs 17.01 crore as of 31 March 2024 .
PBDT rose 32.33% to Rs 314.68 crore. Provision for depreciation rose 34.45% to Rs 56.98 crore. Fixed assets increased to Rs 1,157.96 crore as of 31 March 2025 from Rs 789.51 crore as of 31 March 2024. Intangible assets increased from Rs 2.13 crore to Rs 4.55 crore.
Profit before tax grew 31.87% to Rs 257.70 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 64.2 crore, compared to Rs 18.8 crore. Effective tax rate was 24.91% compared to 9.62%.
Minority interest decreased 79.73% to Rs 0.30 crore. Net profit attributable to owners of the company increased 10.31% to Rs 193.20 crore.
Equity capital stood at Rs 65.57 crore as of 31 March 2025 to Rs 65.57 crore as of 31 March 2024. Per share face Value remained same at Rs 10.00.
Promoters' stake was 40.91% as of 31 March 2025 ,compared to 40.91% as of 31 March 2024 .
Cash flow from operating activities increased to Rs 253.30 crore for year ended March 2025 from Rs 114.52 crore for year ended March 2024. Cash flow used in acquiring fixed assets during the year ended March 2025 stood at Rs 320.73 crore, compared to Rs 85.30 crore during the year ended March 2024.
Business highlights
In Q1 FY26, IPD and OPD revenue grew by 19.6% and 15.5% YoY respectively, indicating strong service utilization across the hospitals. Overall patient volumes increased by 11.7% YoY. Finance cost increased by Rs 7.2 crore in Q1 FY26 due to debt taken for expansion projects. The company's Dombivli project is on track and expected to become operational by Q1 FY27. Construction for Pune II (Bibwewadi) is scheduled to commence in Q3 FY25, and the Mira'Bhayandar project is currently under regulatory approval. In Q1 FY26, depreciation has increased by Rs 10.2 crore primarily due to capitalization of newly added beds. Total Project Capex for Q1 FY26 stood at Rs 40 crore. The company Commissioned a 1.2 MW solar power plant in Madhya Pradesh.Management Comments :
Dr. Ankit Thakker JMD & CEO said, 'We are pleased to report a strong performance in Q1FY26, with Total Income of Rs 347.6 crore along with an EBITDA of Rs 78.1 crore, supported by improved occupancy levels across all units. Our new projects are progressing as per plan, with Dombivli expected to be commissioned in less than a year from now in Q1FY27. The second Pune hospital excavation is progressing as per plan with construction set to begin from Q3FY26. We have commissioned our 1.2 MW solar power plant in Madhya Pradesh, which will add to our existing renewable energy capacity of 5.6 MW of wind energy. Jupiter remains committed to making investments to offset its carbon footprint in pursuit of its sustainability goals. Recognizing the substantial demand-supply mismatch in Western India, we remain focused on exploring strategic expansion opportunities in the region. We have taken on some debt on our books to be ready to capitalize on a suitable opportunity as it arises. This finance cost along with increased depreciation of the ongoing investments will mean that the gap between EBITDA and PBT is expected to be wider in the times to come.'
| Jupiter Life Line Hospitals : Consolidated Results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Powered by Capital Market - Live News